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Background: Mounting evidence indicates that long noncoding RNAs (lncRNAs) could play a pivotal role in cancer
biology. However, the overall biological role and clinical significance of PVT1 in gastric carcinogenesis remains
largely unknown.
Methods: Expression of PVT1 was analyzed in 80 GC tissues and cell lines by qRT-PCR. The effect of PVT1 on proliferation
was evaluated by MTT and colony formation assays, and cell apoptosis was evaluated by Flow-cytometric analysis. GC cells
transfected with shPVT1 were injected into nude mice to study the effect of PVT1 on tumorigenesis in vivo. RIP was
performed to confirm the interaction between PVT1 and EZH2. ChIP was used to study the promoter region of related
genes.
Results: The higher expression of PVT1 was significantly correlated with deeper invasion depth and advanced TNM stage.
Multivariate analyses revealed that PVT1 expression served as an independent predictor for overall survival (p = 0.031).
Further experiments demonstrated that PVT1 knockdown significantly inhibited the proliferation both in vitro and in vivo.
Importantly, we also showed that PVT1 played a key role in G1 arrest. Moreover, we further confirmed that PVT1 was
associated with enhancer of zeste homolog 2 (EZH2) and that this association was required for the repression of p15 and
p16. To our knowledge, this is the first report showed that the role and the mechanism of PVT1 in the progression of
gastric cancer.
Conclusions: Together, these results suggest that lncRNA PVT1 may serve as a candidate prognostic biomarker and
target for new therapies in human gastric cancer.
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Gastric cancer (GC) is the second leading cause of can-
cer death and the most common gastrointestinal malig-
nancy in East Asia [1]. Unfortunately, gastric cancer is
often diagnosed at advanced stage in most patients and
the prognosis is still very poor [2]. Despite efforts in
multiple fields, there has been little improvement in
early diagnosis and treatment of gastric cancer. Thus, a
better understanding of the mechanisms underlying GC
development and progression is essential for improving
prevention, diagnosis and treatment of this disease.
Recent advances in whole-genome sequencing tech-
nology have led to the discovery of a new type of regula-
tion gene, i.e. long noncoding RNAs (lncRNAs), which
are more than 200 bases in length and unable to be
translated into proteins. Emerging evidence suggests that
lncRNAs may play critical roles in cellular development,
differentiation, and many other biological processes [3-5].
The dysregulation of lncRNAs has been shown in various
types of cancer including gastric cancer [6-9]. Molecular
mechanisms of lncRNAs are diverse. They have been
shown to regulate gene expression at multiple levels, in-
cluding chromatin modification, transcription and post-
transcriptional processing. For example, lncRNAs regulate
gene transcription through recruiting transcription factors
to their target gene promoters, therefore activating
gene expression [10]. Moreover, they can also block
binding of transcription factors, potentially via forma-
tion of RNA-DNA-Triplexes [11]. In mammalian cells,
lncRNA HOTAIR interacts with PRC2 (Polycomb Re-
pressive Complex 2) to induce heterochromatin forma-
tion in specific gene loci leading to inactivation of
target genes [12]. Furthermore, lncRNAs can modulate
gene expression in post-transcriptionally levels [13-15].
Increasing amount of evidence suggests that numerous
lncRNAs have been identified to regulate gene expres-
sion through binding to PRC2 in various biological pro-
cesses, especially in cancer [16,17]. PRC2 is involved in
many biological processes, including differentiation,
maintaining cell identity and proliferation, and stem-cell
plasticity [18]. EZH2, a key catalytic subunit of PRC2
(EZH2, SUZ12 and EED), functions as a histone methyl-
transferase that specifically induces histone H3 lysine 27
trimethylation (H3K27me3) to target genes [19]. Overex-
pression of EZH2 is a marker of advanced and meta-
static disease in numerous cancers, including bladder
cancer [20], gastric cancer [21], lung cancer [22], cervical
cancer [23] and hepatocellular carcinoma [24]. So far,
long non-coding RNAs are becoming recognized as im-
portant participants in PRC2 function.
PVT1 oncogene (PVT1) encodes a long noncoding
RNA and maps to chromosome 8q24 [25]. Alvarez ML
et al. has showed that PVT1 may mediate the develop-
ment and progression of diabetic nephropathy throughmechanisms involving ECM accumulation [26]. Amplifi-
cation of PVT1 is one of the most frequent events in a
variety of malignant diseases, including colorectal cancer
[27], serous ovarian and breast cancers [28], and has
been associated with reduced survival duration in pa-
tients. To sum up, the dysregulation of PVT1 involves in
a wide variety of diseases, especially in tumors. However,
the function role and molecular mechanism of PVT1 in
gastric cancer remains unclear.
In the current study, we showed that PVT1 was mark-
edly increased in gastric cancer tissues compared with ad-
jacent non-tumor tissues and could be served as an
independent predictor for overall survival in gastric cancer.
In addition, PVT1 could regulate gastric cancer cell growth
both in vitro and in vivo. Furthermore, PVT1 played a piv-
otal role in G1 arrest through epigenetically regulating the
expression of p15 and p16 by binding to EZH2. Together,
these results indicate that lncRNA PVT1 plays a critical
role in gastric cancer and may serve as a candidate target
for new therapies in human gastric cancer.
Results
PVT1 expression is increased in human gastric cancer
tissues and correlates with poor prognosis
To investigate the role of PVT1 in gastric cancer progres-
sion, we detected the PVT1 expression levels in 80 paired
gastric cancer tissues and corresponding non-tumor tis-
sues by using qRT-PCR, and normalizing to GAPDH. The
transcript levels of PVT1 were significantly up-regulated
in 71.25% (57 of 80) cancerous tissues compared with ad-
jacent non-tumor tissues (p < 0.01) (Figure 1A). Next, we
examined the correlation of PVT1 expression level with
patients’ clinical features in gastric cancer. As shown in
Figure 1B and C, high levels of PVT1 were correlated with
advanced TNM stage (p < 0.05) and deeper invasion depth
(P < 0.01). However, several other clinical parameters were
found not to be significantly correlated with PVT1 ex-
pression in our study (Table 1). The detailed results of
clinical parameters and expressions were shown in
Additional file 1: Table S2.
To explore the relationship between PVT1 expression
and GC patients’ prognosis, we attempted to assess the
correlation between PVT1 expression and clinical out-
comes. The median expression for PVT1 in tumor tis-
sues was used to divide the samples into high (above the
median, n = 40) and low (below the median, n = 40)
PVT1 expression group. Kaplan-Meier analysis and log-
rank test were performed to further evaluate the effects
of PVT1 expression and the clinicopathological charac-
teristics on disease-free survival (DFS) and overall sur-
vival (OS). The results showed that 3 years of disease-
free survival (DFS) for high PVT1 expression is 35.5%,
while is 49.2% for low PVT1 expression. The median
survival time for high PVT1 expression is 12 months,
Figure 1 (See legend on next page.)
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Figure 1 PVT1 expression is increased in human gastric cancer tissues and correlates with poor prognosis. (A) Relative expression of PVT1 in GC tissues
(N = 80) compared with corresponding non-tumor tissues (N = 80). PVT1 expression was detected by qPCR and normalized to GAPDH expression. (B) The
PVT1 expression was significantly higher in patients with higher pathological stage (T3-4) than in those with lower pathological stage (T1-2). (C) The PVT1
expression was significantly higher in patients with deeper depth of invasion than in patients with shallower depth of invasion. Kaplan–Meier analysis of
disease-free survival (D) or overall survival (E) was analyzed according to PVT1 expression levels. *, P < 0.05, **, P < 0.01.
Table 1 Correlation between PVT-1 expression and
clinicopathological characteristics of gastric cancer








































Kong et al. Molecular Cancer  (2015) 14:82 Page 4 of 14while is 28 months for low PVT1 expression (Figure 1D,
Log rank p = 0.001). Moreover, 3 years of overall survival
for high PVT1 expression is 35.7%, while is 48.6% for
low PVT1 expression. The median survival time for high
PVT1 expression is 13 months, while is 25 months for
low PVT1 expression (Figure 1E, Log rank p = 0.002).
To further assess whether PVT1 expression can be
identified as a prognostic predictor for GC patients, the
univariate and multivariate survival analyses (Cox pro-
portional hazards regression model) were performed. By
univariate analysis, we identified three prognostic fac-
tors: TNM stage (I/II, III/IV), distant metastasis and
PVT1 expression, other clinical parameters were not sig-
nificant prognosis factors (Table 2). Further analysis in a
multivariate Cox proportional hazards model, PVT1 ex-
pression and TNM stage were strongly associated with DFS
(p = 0.021, p = 0.023, respectively). Meanwhile, PVT1 ex-
pression and TNM stage were also significantly correlated
with OS in our study cohort (p = 0.031, p = 0.04, respect-
ively). Taken together, these results demonstrated that
PVT1 expression was an independent prognostic indicator
for DFS (HR = 2.216, 95% CI: 1.130-4.345, p = 0.021) and
OS (HR= 2.092, 95% CI: 1.068-4.096, p = 0.031) in patients
with gastric cancer (Table 2).
Amplification of a region on chromosome 8q24 is one
of the most frequent events in carcinomas. The well-
established oncogene MYC maps to this locus and likely
contributes to the pathophysiology of cancers in which it
is amplified. However, the PVT1 transcript also maps to
this region and has been implicated in cancer pa-
thophysiology as well. Several published reports have
revealed that aberrant PVT-1 expression caused by
copynumber amplification of chromosome 8q24 [28,29].
To explore the relationship between PVT1 and 8q24 in
GC, we checked the genomic amplification of PVT1-
MYC region in 30 pairs GC tumor samples by qPCR. As
shown in Additional file 2: Figure S2, Copy-numbers of
8q24 and PVT1 expression were positively correlated in
GC tissues, and Copy-numbers of 8q24 and MYC ex-
pression were also positively correlated in GC tissues.
These findings showed that 8q24 copy-number gain pro-
moted PVT-1 expression in GC.
Knockdown PVT1 inhibits gastric cancer cell proliferation
in vitro
To gain insight into functional role of PVT1 in gastric
cancer, qRT-PCR was performed to detect the expression
Table 2 Univariate and multivariate Cox regression analyses PVT-1 for DFS or OS of patients in study cohort (n = 80)
Variables DFS OS
HR 95% CI p value HR 95% CI p value
Univariate analysis
Age (<50 years vs. >50 years) 0.830 0.448-1.536 0.552 0.854 0.462-1.581 0.616
Gender (male vs. female) 0.716 0.378-1.354 0.304 0.686 0.362-1.299 0.247
Location (Distal vs. Middle + Proximal) 0.711 0.383-1.322 0.281 0.668 0.359-1.241 0.201
Histologic differentiation (Well + Moderately vs. Poorly + Undifferentiated) 1.204 0.642-2.257 0.562 1.198 0.639-2.246 0.572
Invasion depth (T1 + T2 vs. T3 + T4) 0.629 0.370-1.069 0.087 0.863 0.466-1.597 0.639
TNM stage (I + II vs. III + IV) 0.377 0.198-0.720 0.003* 0.396 0.209-0.750 0.004*
Lymphatic metastasis (Yes vs. No.) 0.917 0.674-1.247 0.581 0.920 0.677-1.251 0.596
Regional lymph nodes (PN2+ PN3 vs. PN0+ PN1) 1.717 0.901-3.271 0.192 1.668 0.878-3.169 0.118
Distant metastasis (No vs. Yes) 0.255 0.073-0.892 0.032* 0.191 0.054-0.679 0.011*
Expression of PVT1 (High vs. Low) 2.691 1.418-5.109 0.002* 2.612 1.381-4.942 0.003*
Multivariate analysis
TNM stage (I + II vs. III + IV) 0.457 0.233-0.897 0.023* 0.496 0.254-0.970 0.040*
Lymphatic metastasis (No vs. Yes) NA NA
Regional lymph nodes (PN0+ PN1 vs. PN2+ PN3) NA NA
Distant metastasis (No vs. Yes) 0.525 0.145-1.899 0.326 0.371 0.101-1.361 0.135
Expression of PVT1 (High vs. Low) 2.216 1.130-4.345 0.021* 2.092 1.068-4.096 0.031*
*P<0.05.
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Figure S1A, three cell lines (AGS, SGC-7901, and BGC-
823) expressed higher levels of PVT1 compared with the
normal gastric epithelium cell line (GES-1). The relative
high expression cell lines (SGC-7901, BGC-823) were
chosen for further study. To avoid off-target effects and
ensure the efficiency of interference, we used an indeed ef-
fective interference target sequence of PVT1 according to
previous study [27]. Then PVT1 siRNA was transfected
into SGC-7901 and BGC-823 cell lines. qPCR assays re-
vealed that PVT1 expression was significantly reduced
(Additional file 3: Figure S1B). Next, MTT assay showed
that knockdown of PVT1 expression significantly inhibited
cell proliferation both in SGC-7901 and BGC-823 cell
lines compared with the control cells (Figure 2A). More-
over, colony-formation assay revealed that clonogenic sur-
vival was obviously decreased following inhibition of
PVT1 both in SGC-7901 and BGC-823 cell lines
(Figure 2B). Furthermore, flow cytometric analysis was
performed to further assess whether the effect of PVT1 on
proliferation of GC cells by affecting cell-cycle progression
or apoptosis. The results showed that down-regulation
of PVT1 expression resulted in a significant increase in
the percentages of cells in G1 phase compared with
cells transfected with si-NC (Figure 2C). In addition,
knockdown PVT1 could obviously promote cell apop-
tosis (Figure 2D). These data suggested that aberrant
expression of PVT1 promoted proliferation capability
of gastric cancer cells.The impact of PVT1 on tumorigenesis in vivo
To further determine whether the PVT1 affects tumori-
genesis, we injected SGC-7901 cells transfected with ei-
ther Scramble or shPVT1 into nude mice. In consistent
with in vitro results, tumor growth in shPVT1 group
was obviously slower than that in the Scramble group
(Figure 3A and B). Up to 16 days after injection, the
average tumor weight in shPVT1 group was significantly
lower than that in the control group (Figure 3C). qRT-
PCR analysis was performed to detect the average ex-
pression of PVT1 in tumor tissues. Results demonstrated
that the average level of PVT1 in shPVT1 group was
lower than that in control group (Figure 3C). Moreover,
we also found that the tumors developed from control
cells showed a stronger Ki-67 expression than that in tu-
mors formed from shPVT1, as detected by IHC analysis
(Figure 3D). These data further supported the role of
PVT1 in gastric cancer cell proliferation.
PVT1 is associated with EZH2
Recent studies have reported that lncRNAs recruit
polycomb-group proteins to specific loci and repress
gene expression [12]. Twenty percent of all human
lncRNAs have been shown to physically associate with
Polycomb Repressive Complex 2 (PRC2 complex) [30].
Thus we hypothesized that PVT1 might affect gene ex-
pression in such a manner. Firstly, we detected PVT1
expression in nuclear and cytosolic fractions from SGC-
7901 and BGC-823 cells by qRT-PCR. GAPDH was used
Figure 2 (See legend on next page.)
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Figure 2 Effect of PVT1 on gastric cell growth in vitro. (A) Forty-eight hours after transfection, MTT assay was performed to detect the proliferation of
SGC-7901 and BGC-823 cells. (B) Colony-forming growth assays were performed to determine the proliferation of SGC-7901 and BGC-823 cells. The
colonies were counted and captured. (C) Forty-eight hours after transfection, cell cycle was analyzed by flow cytometry. The bar chart represented the
percentage of cells in G0/G1, S, or G2/M phase, as indicated. (D) Forty-eight hours after transfection, the apoptotic rates of cells were detected by flow
cytometry. LR, early apoptotic cells. UR, terminal apoptotic cells. Error bars indicate means ± S.E.M. *, P < 0.05, **, P < 0.01.
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marker. We found a considerable enrichment of PVT1
in the nucleus versus the cytosol (Figure 4A), suggesting
that PVT1 expression was predominantly nuclear and
PVT1 played a major regulatory function at the tran-
scriptional level. In addition, we performed RNA immu-
noprecipitation by using an antibody against enhancer of
zeste homolog 2 (EZH2; an important subunit of the
PRC2 complex) in SGC-7901 and BGC-823 cells. As
showed in Figure 4B, the endogenous PVT1 was
enriched in the anti-EZH2 RNA immunoprecipitation
(RIP) fraction relative to the input compared with the
IgG fraction in SGC-7901 and BGC-823 cell lines. The
endogenous lncRNA HOTAIR, which binds to PRC2,
was used as positive control. Together, these results
demonstrated a specific association between EZH2 and
PVT1.
PVT1 is required to target EZH2 occupancy and activity to
epigenetically regulate the expression of p15 and p16
To investigate the fact that PVT1 played a role in G1/S
arrest, we assessed the effect of PVT1 inhibition on ex-
pression of cyclin-dependent protein kinase inhibitors byFigure 3 The impact of PVT1 on tumorigenesis in vivo. (A) and (B) Scramble
nude mice (n = 7), respectively. Tumor volumes were calculated every other d
represented as means of tumor weights ± SD. qRT-PCR was performed to det
tumors. The tumor sections were under H&E staining and IHC staining using
**, P < 0.01.qRT-PCR and western blotting, and the results showed
that the mRNA and protein levels of p15, p16 were in-
creased with the knockdown of PVT1 (Figure 5A). The
results suggested that PVT1 may contribute to cell-cycle
arrest through negatively regulating expression of the
tumor suppressor p15 and p16.
We then sought to determine the functional relevance
of the association between PVT1 and EZH2. We asked
whether EZH2 was involved in the repression of p15
and p16. The effectiveness of EZH2 and SUZ12 siRNA
were presented in Additional file 3: Figure S1C. Analysis
with qRT-PCR and western blotting confirmed that the
expression of PRC2 target genes p15 and p16 [16] were
increased when EZH2 was knockdown in SGC-7901 and
BGC-823 cell lines (Figure 5B). Furthermore, p15 and
p16 mRNA levels were also increased when SUZ12 (an-
other important subunit of the PRC2 complex) was
knockdown (Figure 5B).
To address whether PVT1 is involved in transcrip-
tional repression through enrichment of EZH2 to target
gene promoters, we conducted ChIP analysis in SGC-
7901 and BGC-823 cell lines. ChIP assays demonstrated
that knockdown of PVT1 decreased the binding ofor shPVT1 was transfected into SGC-7901 cells, which were injected in the
ay after 4 days of injection. Bars indicate SD. (C) Tumor weights are
ermine the average expression of PVT1. (D) Histopathology of xenograft
antibodies against Ki-67. Error bars indicate means ± S.E.M. *, P < 0.05,
Figure 4 Subcellular fractionation location of PVT1, and PVT1 could bind to EZH2. (A) After nuclear and cytosolic separation, RNA was extracted
from the nuclear and the cytoplasmic fraction of SGC-7901 and BGC-823 cells and PVT1 expression was measured by qRT-PCR. GAPDH was used as a
cytosol marker and U6 was used as a nucleus marker. (B) RIP experiments were performed in SGC-7901 and BGC-823 cells and the coprecipitated RNA
were subjected to qRT-PCR for PVT1. HOTAIR was used as a positive control. The fold enrichment of PVT1 in EZH2 RIP is relative to its matching IgG control
RIP. *, P < 0.05, **, P < 0.01.
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promoters compared to cells transfected with si-NC
(Figure 5C). Importantly, no significant change was de-
tected at the promoter of HOXA9, a target of polycomb
[31] (Additional file 3: Figure S1D). These results suggest
that PVT1 is required to target EZH2 occupancy and ac-
tivity to epigenetically modulate the expression of p15
and p16.
PVT1 is inversely correlated with p15/p16 in GC tissues
To verify the function role of EZH2 in GC, we detected
the expression of EZH2 protein in 30 pairs GC tissues
by IHC. Eighty percent of the tumors showed positive im-
munostaining of EZH2 protein. In contrast, all of the corre-
sponding non-tumor gastric tissues showed negative orweakly positive immunostaining of EZH2 protein. Further
analysis showed that the expression of PVT1 was positively
correlated with EZH2 protein level in GC tissues
(Figure 6A). Moreover, flow cytometric analysis demon-
strated that the cell cycle progression of si-EZH2 cells was
stalled at the G1 phase compared with cells transfected
with si-NC (Figure 6B). These results indicated that EZH2
was up-regulated in GC tissues and played an important
role in gastric cancer cell proliferation. In addition, IHC
was used to detect the expression of p15 and p16 proteins
in gastric cancer and corresponding non-tumor gastric tis-
sues. Most of the non-tumor gastric tissues showed
strongly positive immunostaining of p15 (20/30) and p16
(22/30) proteins. In contrast, the corresponding GC tissues
showed negative or weakly positive immunostaining of p15
Figure 5 (See legend on next page.)
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Figure 6 The expression of PVT1 is inversely correlated with p15/p16 protein level in GC tissues. (A) Immunostaining of EZH2 was negatively or
very weakly positive in non-tumor gastric tissues, but was strongly positive in corresponding tumor tissues. The immunoreactivity of EZH2 protein
in GC tissues showed a statistically significant positive correlation with PVT1 expression. Error bars indicate means ± standard errors of the mean.
(B) Flow cytometry assays were performed to detect the cell cycle after si-EZH2 transfection. (C) The level of p15/p16 in GC tissues was
determined by immunohistochemistry. PVT1 expression was inversely correlated with p15/p16 protein level. *, P < 0.05, **, P < 0.01.
(See figure on previous page.)
Figure 5 PVT1 could regulate the expression of p15/p16 in epigenetic level. (A) qPCR and western blot assays were performed to determine the
expression of p15, p16, p21 and p27 in SGC-7901 and BGC-823 cells after si-PVT1 2# transfection. (B) The expression level of p15 and p16 was detected in
SGC-7901 and BGC-823 cells after si-EZH2 or si-SUZ12 transfection by qPCR and western blot asssy was performed to detect the protein level of p15 and
p16 after si-EZH2 transfection. (C) ChIP of EZH2 and H3K27me3 of the promoter region of p15/p16 locus after siRNA treatment targeting si-NC or si-PVT1 2#
in SGC-7901 and BGC-823 cells, qPCR was performed to detect the quantitation of ChIP assays. Enrichment was quantified relative to input controls.
Antibody directed against IgG was used as a negative control. Error bars indicate means ± S.E.M. *, P < 0.05, **, P < 0.01.
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that the expression of PVT1 was inversely correlated with
p15 and p16 protein levels in GC tissues (Figure 6C).
Discussion
The newly discovered lncRNAs have emerged as an im-
portant player in cellular development and human dis-
eases [32,33]. LncRNAs demonstrate temporal and
tissue-specific expression patterns, and aberrant regula-
tion in various diseases, including cancer [34].
In our present study, we demonstrated that PVT1 ex-
pression was markedly increased in gastric cancer tissues
compared with corresponding non-tumor tissues. The
high expression level of PVT1 in GC patients was asso-
ciated with deeper invasion depth and advanced TNM
stage. In addition, high PVT1 expression in GC tissues
was associated with a poor prognosis and could be an
independent prognostic indicator. Moreover, aberrant
expression of many other lncRNAs has been reported to
be regarded as prognostic indicators. For example,
HOTAIR expression is increased in primary breast tu-
mors and metastases and its expression level in primary
tumors is a powerful predictor of eventual metastasis
and death [12]. Our previous studies also showed that
lncRNA ANRIL and HOTAIR could serve as a prognos-
tic factor in GC [9,35]. In addition, amplification of
chromosome 8q24 is one of the most frequent events in
carcinomas. The well-established oncogene MYC maps
to this locus and likely contributes to the pathophysi-
ology of cancers in which it is amplified. However, the
PVT1 transcript also maps to this region and has been
implicated in cancer pathophysiology as well. Several
published reports have revealed that aberrant PVT-1 ex-
pression caused by copynumber amplification of
chromosome 8q24. Our results showed that 8q24 copy-
number gain promoted PVT-1 expression in GC and
suggested that PVT1 may play an important role in GC
development, and may be useful as a novel prognostic
marker for GC.
PVT1 has been studied in a variety of physiological
and pathological processes, such as diabetic nephropathy
[26], colorectal cancer [27], ovarian and breast cancers
[28]. However, the possible role and molecular mechan-
ism of PVT1 in human gastric cancer remains to be
clarified. As shown in Figures 2 and 3, our results
showed that PVT1 knockdown could significantly inhibit
gastric cancer cell proliferation both in vitro and in vivo.
In addition, flow cytometric analysis indicated that in-
hibitory effect of PVT1-siRNA on proliferation of GC
cells by causing obvious G1 phase arrest and inducing
apoptosis, as shown in Figure 2.
Previous studies have reported that many lncRNAs re-
cruit PRC2 complexes to target genes, and PRC2-
mediated epigenetic regulation has an important role incancer [12]. Twenty percent of all human lncRNAs have
been shown to physically associate with Polycomb Re-
pressive Complex 2 (PRC2 complex), suggesting that
lncRNAs may have a universal role in recruiting
polycomb-group proteins to their target genes [30]. In
our study, cell fractionation revealed that PVT1 was
mainly localized in the nucleus, suggesting the transcrip-
tional regulation mechanism involvement (Figure 4A).
Furthermore, we performed RIP with an antibody
against enhancer of zeste homolog 2 (EZH2; an import-
ant subunit of the PRC2 complex). Encouragingly, the
endogenous PVT1 was enriched in anti-EZH2 RNA im-
munoprecipitation (RIP) fraction relative to the input
compared with the nonspecific IgG fraction both in
SGC-7901 and BGC-823 cell lines (Figure 4B). Our re-
sults suggest that PVT1 serve as a new member of
PRC2-mediated epigenetic regulation and may partici-
pate in the occurrence and development of GC.
To our knowledge, the kinase activity of Cdk/cyclin
complexes is tightly modulated by a plethora of Cdk in-
hibitors (CKIs), which serve as brakes to halt cell cycle
progression [36]. Thus, we assessed the effect of PVT1
inhibition on the expression of several CKI family pro-
teins involved in the G1/S checkpoint in SGC-7901 and
BGC-823. After inhibition of PVT1, we observed a sig-
nificantly increase in the expression of the tumor sup-
pressor p15 and p16 (Figure 5) in transcriptional level.
p15 and p16 belong to INKs family of cyclin-dependent
kinase (cdk) inhibitor proteins; they bind to cycilnD ei-
ther alone or when complexed to their caralytic subunit
CDK4 and prevent the activation of cyclinD-CDK4 com-
plexes, and thus control the cell cycle progression at G1
phase. Indeed, the INK4A-ARF-INK4B gene cluster is
homozygously deleted or silenced in a variety of human
cancers with an estimated frequency of ~ 40%, represent-
ing one of the most frequently cytogenetic events in hu-
man cancers [37-40]. Furthermore, altered expression of
p15 and p16 proteins was associated with GC growth
[41]. These results indicated that PVT1 could regulate
proliferation of gastric cancer cells by affecting the ex-
pression of p15 and p16.
Our study identified EZH2 as an important player in
this PVT1-mediated p15 and p16 repression network be-
cause the ability of PVT1 to repress p15 and p16 was
dependent on the association between PVT1 and EZH2.
As shown in Figure 5B, analysis with qRT-PCR and
western blotting confirmed that the expression of p15
and p16 were increased when EZH2 was knockdown.
Previous studies have showed that ANRIL could epige-
netically regulate p15 and p16 in Cis by binding to PRC2
[16]. In our study, we showed high abundance binding
between PVT1 and EZH2 in gastric cancer cells, and we
further confirmed that PVT1 could mediate epigenetic
regulation of p15 and p16 in Trans. As shown in
Kong et al. Molecular Cancer  (2015) 14:82 Page 12 of 14Figure 5C, ChIP-qPCR assays determined that PVT1
was required for the EZH2 recruitment to and silencing
of p15 and p16. Moreover, overexpression of EZH2 has
been described in cancers including bladder [20], gastric
[21], lung [22], and hepatocellular carcinoma [24]. To
further validate the role of EZH2 in gastric cancer, we
detected the EZH2 expression in 30 pairs of gastric can-
cer tissues and corresponding adjacent tissues by IHC
analysis and found that EZH2 was up-regulated in gas-
tric cancer tissues, and the expression of EZH2 was posi-
tively correlated with PVT1 expression (Figure 6A).
Importantly, we detected a significant G1 phase arrest
after si-EZH2 transfection (Figure 6B). This was consist-
ent with the effect of PVT1. To determine the clinical
relevance of PVT1 and p15/p16, we detected p15/p16
expression in GC tissues by IHC and found inverse rela-
tionship between the expression of p15/p16 and PVT1
(Figure 6C). Our finding adds a new piece (PVT1) to
p15 and p16 tumor suppressor regulatory network. And
p15 and p16 act as tumor suppressors in various can-
cers, and aberrant methylation in p15 and p16 gene pro-
moter region has been linked to gene downregulation of
expression. And PRC2-mediated histone methylation
contributes to the repression of p15 and p16. Our results
explained that how p15 and p16 are specifically regu-
lated by PRC2, due to in part through PVT1. Taken to-
gether, we identified that PVT1 played an oncogenic role
in gastric cancer partly through epigenetic regulation of
p15 and p16.
In a broader perspective, the identification of PVT1 as
an important prognostic factor for GC patients calls our
attention to exploring its functional roles. Moreover,
PVT1 could regulate gastric cancer cells proliferation
both in vitro and in vivo. Importantly, we first reported
that PVT1 serving as a member of PRC2-mediated epi-
genetic regulation participated in the development of
gastric cancer. Our study may provide a strategy and fa-
cilitate the development of lncRNA directed diagnostics
and therapeutics against this deadly disease.
Materials and methods
Cell culture
Three gastric cancer cell lines (AGS, SGC-7901, BGC-
823), and a normal gastric epithelium cell line (GES-1)
were purchased from the Institute of Biochemistry and Cell
Biology of the Chinese Academy of Sciences (Shanghai,
China). Cells were cultured in RPMI 1640 or DMEM with
10% FBS (Gibco), and cultured at 37°C with 5% CO2.
Tissue samples and clinical data collection
Human gastric cancer specimens were obtained from
the First Affiliated Hospital of Nanjing Medical Univer-
sity. This study was approved by Research Ethics Com-
mittee of Nanjing Medical University (Nanjing, Jiangsu,PR China). Written informed consent was obtained from
all patients. Corresponding normal gastric tissue samples
were taken from tissues that were located 5 cm away
from tumor margin. The characteristics of the patients
were summarized in Table 1.
RNA extraction and qRT-PCR analyses
Total RNA was extracted from gastric cancer tissues or
cells by using TRIzol reagent (Invitrogen), according to
the manufacturer’s protocol. RNA was reverse tran-
scribed to cDNA by using a Reverse Transcription Kit
(Takara, Dalian, China). Real-time PCR was performed
with SYBR Green (Takara, Dalian China). GAPDH was
used as reference for mRNA or lncRNAs. Each sample
was analyzed in triplicate. The primers were listed in
Additional file 4: Table S1.
RNA interference
Gastric cancer cells were transfected with siRNA by
using Lipofectamine 2000 (Invitrogen, USA), according
to the manufacturer’s protocol. The cells were in-
cubated for 48 h before use in assays. The siRNA
sequences were listed in Additional file 4: Table S1.
The shRNA PVT1 (CCCAACAGGAGGACAGCTT)
was cloned into pENTR™/U6 vector.
Cell proliferation assays
Cell proliferation was tested with MTT kit (Sigma) accord-
ing to the manufacturer’s instruction. For colony formation
assay, a certain number of transfected cells were placed in
each well of a six-well plate and maintained in proper
media containing 10% FBS for two weeks, during which
the medium was replaced every 4 days. Colonies were then
fixed with methanol and stained with 0.1% crystal violet
(Sigma) in PBS for 10 minutes. Colony formation was de-
termined by counting the number of stained colonies.
Flow-cytometric analysis
Transfected cells were harvested after 48 h transfection.
After the double staining with fluorescein isothiocyanate
(FITC)-Annexin V and propidium iodide was done by
the FITC Annexin V Apoptosis Detection Kit (BD Bio-
sciences) according to the manufacturer’s recommenda-
tions. The cells were analyzed with a flow cytometry
(FACScan; BD Biosciences) equipped with a Cell Quest
software (BD Biosciences). Cells were discriminated into
viable cells, dead cells, early apoptotic cells, and apop-
totic cells, and then the relative ratio of early apoptotic
cells were compared with control transfection from each
experiment. Cells for cell-cycle analysis were stained
with propidium oxide by the CycleTEST PLUS DNA Re-
agent Kit (BD Biosciences) following the protocol and
analyzed by FACScan. The percentage of the cells in
G0–G1, S, and G2–M phase were counted and compared.
Kong et al. Molecular Cancer  (2015) 14:82 Page 13 of 14Western blot assay and antibodies
Cells protein lysates were separated by 15% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) trans-
ferred to 0.22 μm NC membranes (Sigma) and incubated
with specific antibodies. GAPDH antibody was used as
control. Autoradiograms were quantified by densitometry
(Quantity One software; Bio-Rad). Anti-p15 and anti-p16
were purchased from Santa Cruz Biotechnology, Inc.
Anti-Ki67 was purchased from Santa Cruz Biotechnology.
Subcellular fractionation location
The separation of nuclear and cytosolic fractions was per-
formed using the PARIS Kit (Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
RNA immunoprecipitation (RIP)
RNA immunoprecipitation(RIP) experiments were per-
formed by using a Magna RIP™ RNA-Binding Protein
Immunoprecipitation Kit (Millipore, USA) according to
the manufacturer’s instructions. Antibody for RIP assays
of EZH2 was from Abcam.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed using EZ-CHIP KIT accord-
ing to the manufacturer’s instruction (Millipore, USA).
EZH2 antibody was obtained from Abcam. H3 trimethyl
Lys 27 antibody was from Millipore. The ChIP primer se-
quences were listed in Additional file 4: Table S1. Quanti-
fication of immunoprecipitated DNA was performed
using qPCR with SYBR Green Mix (Takara). ChIP data
was calculated as a percentage relative to the input DNA
by the equation 2[Input Ct − Target Ct] × 0.1 × 100.
Animal work
Animal work was performed according to the proce-
dures as previously described [9]. 5-week-old male athy-
mic BALB/c mice were maintained under specific
pathogen-free conditions and manipulated according to
protocols approved by the Shanghai Medical Experimen-
tal Animal Care Commission. SGC-7901 cells trans-
fected with Scramble or shPVT1 were harvested at a
concentration of 2 × 107 cells/ml. Of the suspending
cells, 0.1 ml was subcutaneously injected into the flanks
of the nude mouse, one injection per mouse. Tumor
growth was monitored, and tumor sizes and weights
were measured every two days. Tumor volume was cal-
culated using the formula, volume = (length × width2 ×
0.5). Sixteen days after injection, the mice were killed
and tumor weights were measured and used for further
analysis. The primary tumors were excised and tumor
tissues were used to perform qRT-PCR analysis of PVT1
expression levels and immunostaining analysis of Ki-67
protein expression.Immunohistochemistry (IHC)
The primary tumors were immunostained for Ki-67 as
previously described [17].
Statistical analysis
All statistical analyses were performed by using SPSS
20.0 software (IBM, SPSS, USA). The significance of dif-
ferences between groups was estimated by Student’s t-
test, χ2 test or Wilcoxon test, as appropriate. DFS and
OS rates were calculated by the Kaplan-Meier method
with the log-rank test applied for comparison. Survival
data were evaluated using univariate and multivariate
Cox proportional hazards model. Variables with a value
of p < 0.05 in univariate analysis were used in subsequent
multivariate analysis on the basis of Cox regression ana-
lyses. Two-sided p-values were calculated, and a probabil-
ity level of 0.05 was chosen for statistical significance.
Additional files
Additional file 1: Table S2. The detailed results of clinical parameters
and expressions.
Additional file 2: Figure S2. qPCR was used to check relationship
between the genomic amplification of 8q24 and expression of PVT1/MYC
in 30 pairs GC samples.
Additional file 3: Figure S1. Supplementary experimental results.
(A) PVT1 was detected in GC cells by qRT-PCR, data was presented as
fold-change in GC cell lines (AGS, SGC-7901, BGC-823) relative to
GES-1 cell line. (B) The relative expression level of PVT1 in SGC-7901
and BGC-823 cells, transfected with si-NC or si-PVT1 (si-PVT1 1#, 2#),
was tested by qPCR. (C) The relative expression level in SGC-7901 and
BGC-823 cells, after knockdown EZH2 and SUZ12, was tested by qPCR.
(D) ChIP-qPCR of H3K27me3 and EZH2 of the promoter region of
HOXA9 after siRNA treatment targeting si-NC or si-PVT1 in SGC-7901
cells. Antibody enrichment was quantified relative to the amount of
input DNA. *, P < 0.05, **, P < 0.01.
Additional file 4: Table S1. The list of primers and the sequence of siRNAs.
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